Review of NICE Technology Appraisal Guidance No.317; Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)

 Proposal to move the existing guidance to the static list

 As you may be aware the planned date for review of the above guidance was June 2017.

 This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

 No new evidence has been identified that would lead to a change in the existing recommendations.    

 Consequently we propose that TA317 should move to the ‘static list’ of technology appraisals.

 Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

 In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.

Please see appendix A for a full list of the organisations we have contacted. 


This page was last updated: